Interstitial Lung Disease as a Late Occurrence in Ocrelizumab-Treated Patients With Multiple Sclerosis

JAMA Neurology 2026 Open access

Read full text
Authors: Anna Żurawska, Anne H. Cross, Katarzyna Rzeszutek, Agnieszka Rogozińska-Zawiślak, Krzysztof Selmaj
DOI: 10.1001/jamaneurol.2026.0548
Cited by: 3
References: 6

Abstract

This case series describes 6 cases of interstitial lung disease among patients with multiple sclerosis receiving long-term treatment with ocrelizumab.

Fields of Study & Subjects

Multiple Sclerosis Research Studies Peripheral Neuropathies and Disorders Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Publication details

Journal / source
JAMA Neurology
Publisher
American Medical Association (AMA)
Volume
83
Issue
5
Pages
505–505
Publication date
6 April 2026
Language
EN